Targeted delivery via biodegradable polymers

Details Targeted delivery via biodegradable polymers Targeted delivery via biodegradable polymers

2005-06-28

2005-06-28

Kishore, Gollamudi S. (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Particulate form

C424S501000, C424S423000, C514S002600, C514S021800, C514S964000, C514S965000, C514S824000

Reexamination Certificate

active

06911216

ABSTRACT:
Delivery of bioactive molecules such as nucleic acid molecules encoding a protein can be significantly enhanced by immobilization of the bioactive molecule in a polymeric material adjacent to the cells where delivery is desired, where the bioactive molecule is encapsulated in a vehicle such as liposomes which facilitates transfer of the bioactive molecules into the targeted tissue. Targeting of the bioactive molecules can also be achieved by selection of an encapsulating medium of an appropriate size whereby the medium serves to deliver the molecules to a particular target. For example, encapsulation of nucleic acid molecules or biologically active proteins within biodegradable, biocompatible polymeric microparticles which are appropriate sized to infiltrate, but remain trapped within, the capillary beds and alveoli of the lungs can be used for targeted delivery to these regions of the body following administration to a patient by infusion or injection.

REFERENCES:
patent: 3663588 (1972-05-01), Evans
patent: 3949068 (1976-04-01), Polin
patent: 4345588 (1982-08-01), Widder
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 4708861 (1987-11-01), Popescu et al.
patent: 4745160 (1988-05-01), Churchill et al.
patent: 4897308 (1990-01-01), Vanlerberghe et al.
patent: 4904479 (1990-02-01), Illum et al.
patent: 5057304 (1991-10-01), Kretzschmar
patent: 5194654 (1993-03-01), Hostetler et al.
patent: 5206023 (1993-04-01), Hunziker
patent: 5223263 (1993-06-01), Hostetler et al.
patent: 5231580 (1993-07-01), Cheung et al.
patent: 5238470 (1993-08-01), Tolles et al.
patent: 5264618 (1993-11-01), Felgner et al.
patent: 5288502 (1994-02-01), McGinity et al.
patent: 5290552 (1994-03-01), Sierra
patent: 5328471 (1994-07-01), Slepian
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5419917 (1995-05-01), Chen et al.
patent: 5423778 (1995-06-01), Eriksson et al.
patent: 5494677 (1996-02-01), Giampapa
patent: 5512294 (1996-04-01), Li et al.
patent: 5591625 (1997-01-01), Gerson et al.
patent: 5607694 (1997-03-01), Marx
patent: 5626863 (1997-05-01), Hubbell et al.
patent: 5652225 (1997-07-01), Isner
patent: 5858345 (1999-01-01), Charles
patent: 0 248 531 (1987-12-01), None
patent: 0 620 277 (1994-10-01), None
patent: WO 85/03640 (1985-02-01), None
patent: WO 90/11092 (1990-10-01), None
patent: WO 92/05866 (1991-10-01), None
patent: WO 93/00051 (1992-06-01), None
patent: WO 93/14778 (1993-08-01), None
patent: WO 93/16687 (1993-09-01), None
patent: WO 93/17669 (1993-09-01), None
patent: WO 94/23699 (1994-10-01), None
patent: WO 94/24962 (1994-11-01), None
patent: WO 94/27612 (1994-12-01), None
patent: WO 94/29469 (1994-12-01), None
patent: WO 95/22316 (1995-02-01), None
Arras, Nature Biotechnology 16:159-162 (1998).
Battler, et al., “Intracoronary Injection of Basic FibroblastGrowth Factor and Angiogenesis in Infarcted Swine Myocardium,”J. Am. Coll. Cariol.22:2001-2006 (1993).
Beck, L.R., et al., “A New Long-Acting Injectable Microcapsule System for the Administration of Progesterone,”Fertil. Steril., 31, 545 (1979).
Benita, S., et al., “Characterization of Drug-Loaded Poly(d,l-lactide) Microspheres,”J. Pharm. Sci., 73, 1721 (1984).
Debs, Robert J., et al., “Transfections of animal cells in vivo with DNA in cationic liposomes for gene therapy,” CA Selects: Controlled Release Technology, Abstract 120:86450c (1994).
Finkel, Toren and Stephen E. Epstein, “Gene therapy for vascular disease,”FASEB9:843-850 (1995).
Flaim, et al., “Multiple Simultaneous Determinations of Hemodynamics and Flow Distribution in Conscious Rat,”J. Pharmacol. Meth.11:1-39 (1984).
Heymann, et al., “Blood Flow Measurements with Radionuclide-labeled Particles,”Prog. Cardiovasc. Dis.20:55-79 (1977).
Hill-West, J., “Prevention of Postoperative Adhesions in the Rat by In Situ Photopolymerization of Bioresorbable Hydrogel Barriers,”Obst.&Gynecol.83:59-64 (1994).
Hill-West et al., “Inhibition of thrombosis and intimal thickening by in situ photopolymerization of thin hydrogel barriers,”Proc. Nat. Acad. Sci.USA 91:5967-5971 (1994).
Leclerc, Guy, et al., “Percutaneous Arterial Gene Transfer in a Rabbit Model,”J. Clin. Invest.90:936-944 (1992).
Losordo, Douglas, W., et al., “Use of the Rabbit Ear Artery to Serially Assess Foreign Protein Secretion After Site-Specific Arterial Gene Transfer In Vivo,”Circulation89:785-792 (1994).
Mathiowitz, E., et al., “Novel Microcapsules for Delivery Systems,”Reactive Polymers, 6, 275 (1987).
Mathiowitz, E., et al., “Morphology of Polyanhydride Delivery System,”J. Scanning Microscopy, 4, 329 (1990).
Morgan, Richard A. and W. French Anderson, “Human Gene Therapy,”Ann. Rev. Biochem., 62:191 (1993).
Mulligan, Richard C., “The Basic Science of Therapy,”Science260:926 (1993).
Nabel, Elizabeth G., et al., “Transduction of a foreign histocompatibility gene into the arterial wall induces vasculitis,”Proc. Natl. Acad. Sci. USA89:5157-5161 (1992).
Nabel, Elizabeth G., et al., “Site-Specific Gene Expression in Vivo by Direct Gene Transfer into the Arterial Wall,”Reports1285-1287 (1990).
Nikol, Sigrid, et al., “Expression of Transforming Growth Factor-β-1 Is Increased in Human Vascular Restenosis Lesions,”J. Clin. Invest.90:1582-1592 (1992).
Ohno, Takeshi, et al., “Gene Therapy for Vascular Smooth Muscle Cell Proliferation After Arterial Injury,”Science265:781-784 (1994).
Ouriemchi, E.M., et al., “Dosage Form for Controlled Delivery to the Intestine of a Drug Soluble in Gastric Liquid and Poorly Soluble in Intestinal Liquid,”J. of Polymer Eng.13:73-85 (1994).
O'Mullane, et al., Annals of the new York Acad Sci., 507:121-140 (1987).
Pickering, J. Geoffrey, et al., “Liposome-Mediated Gene Transfer Into Human Vascular Smooth Muscle Cells,”Circulation89:13-20 (1994).
Pu, Li-Qun, et al., “Angiogenic Growth Factor and Revascularization of the Ischemic Limb: Evaluation in a Rabbit Model,”J. Surg. Res.54:575-583 (1993).
Pu, et al., “Vascular endothelial growth factor induces dose-dependent revascularization in a rabbit model of persistent limb ischemia,”Circulation88(4):147 (1993) Abstract No. 0780.
Rosenfeld, Kenneth, et al., “Images in Clinical Medicine,”New England Journal of Medicinep. 620 (Aug. 26, 1993).
Takeshita, Satoshi, et al., “Increased Gene Expression after Liposome-mediated Arterial Gene Transfer Associated with Intimal Smooth Muscle Cell Proliferation,”J. Clin. Invest., 93:652-661 (1994).
Takeshita, Satoshi, et al., “Therapeutic Angiogenesis,”J. Clin. Invest., 93:662-670 (1994).
Takeshita, Satoshi, et al., “In Vivo Evidence of Enhanced Angiogenesis Following Direct Arterial Gene Transfer of the Plasmid Encoding Vascular Endothelial Growth Factor,”Circulation88(4):476 (1993) Abstract No. 2565.
Tolstoshev, Paul, “Gene Therapy, Concepts, Current Trials and Future Directions,”Ann. Rev. Pharm. Toxicol., 32:573 (1993).
Vandorpe et al. Biomaterials 18(17):1147-1152 (1997).
Anderson, “Clinical phamacokinetic advantages of new drug delivery methods for the treatment of liver tumors,”Clinical Pharmacokinet27(3):191-201 (1994).
Davis, et al., “Microspheres for targeting drugs to specific body sites,”J Controlled Release24:157-63 (1993).
Debs, et al., “Selective enhancement of pentamidine uptake in the lung by aerosolization and delivery in liposomes,”Am Rev Respir Dis135(3):731-737 (1987).
Kerr, et al.,Cancer62:878-883 (1988).
Madoule, et al., “Chemoembolization: Principle and Perspectives,”J Microencapsul1(1):21-25 (1984).
Menstrup, “Validierung der Herstellung und Depoteffekt wirkostoffhaltiger Liposomen,” PhD Thesis, University of Heidelberg, 1988).
Tripathi, et al., “Aminophylline targeting to lung: optimization of the size and drug loading

Affiliated with

Also associated with

Rating

Targeted delivery via biodegradable polymers does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Targeted delivery via biodegradable polymers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Targeted delivery via biodegradable polymers will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3466723